• Home
  • News & Insights
  • Stephenson Harwood advises BTG on US$110 million interventional medicine acquisition

10 May 2016

Stephenson Harwood advises BTG on US$110 million interventional medicine acquisition

Linkedin

International law firm Stephenson Harwood LLP has advised healthcare company BTG PLC on its acquisition of Galil Medical, a US-based kidney cancer treatment company, in a deal worth up to US$110 million.

FTSE 250-listed BTG will pay an initial cash consideration of US$84.5 million to acquire Galil, plus up to US$25.5 million in future regulatory and commercial milestone payments through to the end of 2018. Galil is a privately-owned company based in Minnesota which owns, manufactures and sells a portfolio of cryoablation systems and needles used for treating kidney and other types of cancer.

The Stephenson Harwood team was led by partner Andrew Edge, head of the firm’s corporate practice.

Morgan, Lewis & Bockius’ Princeton office and Israeli firm Goldfarb Seligman also advised BTG.

Linkedin

KEY CONTACT

Andrew Edge

Andrew Edge
Partner

T:  +44 20 7809 2102 M:  +44 7771 921 780 Email Andrew | Vcard Office:  London

MEDIA CONTACT

Andrew Rieley
Head of Communications

T: +44 20 7809 2886
Email Andrew Rieley

  • Related Services
  • Related Locations